ATE548386T1 - Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften - Google Patents
Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaftenInfo
- Publication number
- ATE548386T1 ATE548386T1 AT08168439T AT08168439T ATE548386T1 AT E548386 T1 ATE548386 T1 AT E548386T1 AT 08168439 T AT08168439 T AT 08168439T AT 08168439 T AT08168439 T AT 08168439T AT E548386 T1 ATE548386 T1 AT E548386T1
- Authority
- AT
- Austria
- Prior art keywords
- lobuline
- immuno
- domains
- synthetic
- regions
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64114405P | 2005-01-05 | 2005-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE548386T1 true ATE548386T1 (de) | 2012-03-15 |
Family
ID=36445146
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08168439T ATE548386T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT06121439T ATE414718T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT06703578T ATE425186T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT06011173T ATE423140T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06121439T ATE414718T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT06703578T ATE425186T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT06011173T ATE423140T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
Country Status (23)
Country | Link |
---|---|
US (8) | US20090298195A1 (de) |
EP (4) | EP1752471B9 (de) |
JP (3) | JP4937138B2 (de) |
KR (2) | KR20130105885A (de) |
CN (2) | CN103555733A (de) |
AT (4) | ATE548386T1 (de) |
AU (1) | AU2006204459B2 (de) |
BR (1) | BRPI0606399A8 (de) |
CA (1) | CA2594356C (de) |
CY (3) | CY1108767T1 (de) |
DE (3) | DE602006005526D1 (de) |
DK (4) | DK2028193T3 (de) |
EA (1) | EA018897B1 (de) |
ES (4) | ES2384039T3 (de) |
HR (3) | HRP20090087T3 (de) |
IL (1) | IL184103A (de) |
MX (1) | MX2007008118A (de) |
NZ (1) | NZ555893A (de) |
PL (3) | PL1772465T3 (de) |
PT (4) | PT2028193E (de) |
RS (3) | RS50785B (de) |
SI (3) | SI1752471T1 (de) |
WO (1) | WO2006072620A1 (de) |
Families Citing this family (205)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2629397T3 (es) | 2004-09-24 | 2017-08-09 | Amgen Inc. | Moléculas de Fc modificadas |
PT2028193E (pt) | 2005-01-05 | 2012-06-15 | Star Biotech Forschung Entw Gmbh | Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
AT503902B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
AT503889B1 (de) * | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
EP1975178A1 (de) * | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transzytotischer modularer Antikörper |
WO2008124858A2 (en) * | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
US8541553B2 (en) | 2007-05-24 | 2013-09-24 | Baxter Healthcare Sa | Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein |
US8921279B2 (en) | 2007-06-26 | 2014-12-30 | F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H | Display of binding agents |
KR102467302B1 (ko) | 2007-09-26 | 2022-11-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US20110189206A1 (en) * | 2008-01-03 | 2011-08-04 | Barbas Iii Carlos F | Antibody Targeting Through a Modular Recognition Domain |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
JP5889533B2 (ja) | 2008-01-31 | 2016-03-22 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改変された抗体定常ドメイン分子 |
AU2014200215B2 (en) * | 2008-01-31 | 2016-09-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
EP2113255A1 (de) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Zytotoxisches Immunglobulin |
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
EP3281955A1 (de) | 2008-10-02 | 2018-02-14 | Aptevo Research and Development LLC | Multitarget-bindungsproteine mit cd86-antagonist |
US8580267B2 (en) | 2008-12-19 | 2013-11-12 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
CN101609096B (zh) * | 2009-07-21 | 2012-11-07 | 上海师范大学 | 肺癌标志物检测免疫层析试纸的制备方法 |
US8679488B2 (en) | 2009-08-05 | 2014-03-25 | Philogen S.P.A. | Targeting of bone marrow neovasculature |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2516467A2 (de) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Zusammensetzungen mit tnf-alpha- und il-6-antagonisten und verwendungsverfahren dafür |
DK2519543T3 (en) | 2009-12-29 | 2016-09-26 | Emergent Product Dev Seattle | HETERODIMER BINDING PROTEINS AND USE THEREOF |
WO2011100565A2 (en) * | 2010-02-12 | 2011-08-18 | Research Corporation Technologies | Multimeric proteins comprising immunoglobulin constant domains |
EP2407487A1 (de) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispezifische modulare Antikörper |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
US8637641B2 (en) | 2010-07-29 | 2014-01-28 | Xencor, Inc. | Antibodies with modified isoelectric points |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
JP2014500879A (ja) | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bcma発現に相関性を有する疾患を治療する因子及び方法 |
MX2013007067A (es) | 2010-12-20 | 2013-11-01 | Medimmune Ltd | Anticuerpos anti-il-18 y sus usos. |
WO2012109553A2 (en) * | 2011-02-11 | 2012-08-16 | Research Corporation Technologies | Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds |
AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
CN107903325B (zh) | 2011-05-16 | 2021-10-29 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
EP2728002B1 (de) | 2011-06-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerisiertes polypeptid |
EP2546268A1 (de) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalisierendes Immunglobulin |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
CN104302665B (zh) * | 2011-12-21 | 2019-04-23 | 安姆根有限公司 | 与新生儿Fc受体的结合增强的变体Fc多肽 |
JP6413127B2 (ja) * | 2012-01-09 | 2018-10-31 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 変異抗体およびそのコンジュゲーション |
CN102585000B (zh) * | 2012-02-22 | 2013-05-29 | 尉军 | 一种肿瘤标志物cd25自身抗体及应用 |
WO2013138643A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
CN104583239B (zh) | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
JP6321633B2 (ja) * | 2012-06-04 | 2018-05-09 | ノバルティス アーゲー | 部位特異的標識法およびそれによって生成される分子 |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
KR20230110836A (ko) | 2012-08-24 | 2023-07-25 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc영역 개변체 |
RU2689674C2 (ru) | 2012-10-15 | 2019-05-28 | Медиммьюн Лимитед | Антитела к бета-амилоиду |
CA2893767C (en) | 2012-12-05 | 2022-11-08 | Novartis Ag | Compositions and methods for antibodies targeting epo |
DK2940135T5 (da) | 2012-12-27 | 2021-09-20 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
AU2014207549B2 (en) | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2762496A1 (de) | 2013-02-05 | 2014-08-06 | EngMab AG | Verfahren zur Auswahl von Antikörpern gegen BCMA |
US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
ES2786253T3 (es) | 2013-03-14 | 2020-10-09 | Immusoft Corp | Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
EP2968541A4 (de) | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Multivalente und monovalente multispezifische komplexe und deren verwendungen |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
EP2982689B1 (de) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Varianten der fc-region |
EP2789630A1 (de) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispezifische Antikörper gegen CD3e und ROR1 |
WO2014177460A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
JP6543626B2 (ja) | 2013-07-29 | 2019-07-10 | ブルーバード バイオ, インコーポレイテッド | 多部分シグナル伝達タンパク質およびその使用 |
KR101800295B1 (ko) | 2013-09-04 | 2017-12-20 | 엘지디스플레이 주식회사 | 위치감지방법, 위치감지장치, 안테나 장치 및 디스플레이 장치 |
GB201317622D0 (en) * | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
CN105873952A (zh) | 2013-10-31 | 2016-08-17 | 弗莱德哈钦森癌症研究中心 | 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途 |
CN113307873A (zh) * | 2013-11-11 | 2021-08-27 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
BR112016014156A8 (pt) | 2013-12-20 | 2023-04-11 | Hutchinson Fred Cancer Res | Moléculas efetoras quiméricas etiquetadas e receptores das mesmas |
EP3842455A1 (de) * | 2014-01-15 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region-varianten mit verbesserter protein-a-bindung |
CN107172880B (zh) * | 2014-03-24 | 2021-09-28 | 癌症研究技术有限公司 | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 |
AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
EP3164417A1 (de) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispezifische heterodimere diabodies und verwendungen davon |
TWI679259B (zh) | 2014-08-11 | 2019-12-11 | 德商漢高智慧財產控股公司 | 光學透明的熱熔黏著劑及其用途 |
AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
TWI740809B (zh) | 2014-11-11 | 2021-10-01 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
MX2017006918A (es) | 2014-11-26 | 2018-01-25 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38. |
PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
US10982008B2 (en) | 2014-12-05 | 2021-04-20 | Merck Patent Gmbh | Domain-exchanged antibody |
CA2971430A1 (en) | 2014-12-19 | 2016-06-23 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL297418B2 (en) | 2015-02-18 | 2023-11-01 | Enlivex Therapeutics Rdo Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
EP3265481B1 (de) | 2015-03-05 | 2024-05-01 | Fred Hutchinson Cancer Center | Immunomodulatorische fusionsproteine und verwendungen davon |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
EP3285877B1 (de) | 2015-04-21 | 2022-10-19 | Enlivex Therapeutics Rdo Ltd | Therapeutische gepoolte blutapoptotische zellpräparate und verwendungen davon |
WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
EP3288569A4 (de) | 2015-04-29 | 2018-12-19 | Fred Hutchinson Cancer Research Center | Modifizierte hämatopoietische stamm-/vorläuferzellen und non-t effektorzellen sowie verwendungen davon |
EP3297672B1 (de) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispezifische bindungsproteine und verfahren zur verwendung |
EP3670535A1 (de) | 2015-08-03 | 2020-06-24 | EngMab Sàrl | Monoklonale antikörper gegen bcma |
CN107922975B (zh) | 2015-08-12 | 2022-06-28 | 诺华股份有限公司 | 治疗眼科病症的方法 |
CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
ES2880682T3 (es) * | 2015-10-05 | 2021-11-25 | Fredax Ab | Anticuerpos anti PSA (5A10) humanizados |
EP3387013B1 (de) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Cd3 und psma bindende heterodimere antikörper |
AU2017219415B2 (en) | 2016-02-18 | 2023-08-10 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US10982136B2 (en) | 2016-02-26 | 2021-04-20 | The Regents Of The University Of California | Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters |
CN105664157A (zh) * | 2016-03-11 | 2016-06-15 | 江苏亲合力病毒检测工程有限公司 | 一种抗巨细胞病毒人源化抗体药物 |
KR20180119670A (ko) | 2016-03-15 | 2018-11-02 | 아스트라제네카 아베 | 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합 |
US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
AU2017248259A1 (en) * | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
AU2017250295B2 (en) | 2016-04-14 | 2022-08-25 | Fred Hutchinson Cancer Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
KR102365977B1 (ko) | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
RU2767357C2 (ru) | 2016-06-14 | 2022-03-17 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
ES2858091T3 (es) | 2016-06-20 | 2021-09-29 | F Star Therapeutics Ltd | Moléculas de unión que se unen a PD-L1 y LAG-3 |
BR112018076525A2 (pt) | 2016-06-20 | 2019-04-02 | F-Star Beta Limited | membros de ligação a lag-3 |
CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
WO2018014001A1 (en) | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
EP3503930A4 (de) | 2016-08-29 | 2020-08-05 | Fred Hutchinson Cancer Research Center | Chelatbildende plattform zur abgabe von radionukliden |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018048812A1 (en) | 2016-09-06 | 2018-03-15 | The Regents Of The University Of California | Formulations of hydroxypyridonate actinide/lanthanide decorporation agents |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
WO2018071919A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
EP3544997A4 (de) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | Prostataspezifisches membranantigenbindendes proteine |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
WO2018106993A1 (en) * | 2016-12-09 | 2018-06-14 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tlr9-binding chimeric antigen receptors |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
EP3583120B1 (de) * | 2017-02-17 | 2022-10-05 | Denali Therapeutics Inc. | Manipulierte, an transferrinrezeptor bindende polypeptide |
ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
AU2018236461A1 (en) | 2017-03-17 | 2019-09-19 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
EP3621648A4 (de) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | Auf trispezifische proteine abzielendes msln und verfahren zur verwendung |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
WO2019070577A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
EP3723787A4 (de) | 2017-12-14 | 2021-09-01 | Bluebird Bio, Inc. | Daric-interleukinrezeptoren |
CN111741976A (zh) * | 2017-12-19 | 2020-10-02 | F星贝塔有限公司 | 包括pd-l1抗原结合位点的fc结合片段 |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
JP2021518343A (ja) | 2018-03-15 | 2021-08-02 | 中外製薬株式会社 | ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法 |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US10640576B2 (en) | 2018-04-10 | 2020-05-05 | Y-Biologics Inc. | Cell engaging binding molecules |
JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
WO2019222278A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Dual binding moiety |
BR112020023330A2 (pt) * | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
CN112584862A (zh) * | 2018-05-17 | 2021-03-30 | 伊米若梅有限公司 | Ch3结构域表位标签 |
GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
SG11202100172XA (en) | 2018-07-12 | 2021-02-25 | F Star Beta Ltd | Antibody molecules that bind cd137 and ox40 |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
BR112021000394A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
AU2019318031A1 (en) | 2018-08-10 | 2021-02-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-CD137 antigen-binding molecule and utilization thereof |
US20220098613A1 (en) | 2018-09-12 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
US20220054544A1 (en) * | 2018-09-21 | 2022-02-24 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
KR20210095139A (ko) | 2018-10-17 | 2021-07-30 | 바이오라인알엑스 리미티드 | 전이성 췌장 선암종의 치료 방법 |
MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
KR20210149779A (ko) | 2019-04-10 | 2021-12-09 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 개변 항체의 정제 방법 |
JP2022539248A (ja) | 2019-07-02 | 2022-09-07 | フレッド ハッチンソン キャンサー リサーチ センター | 組換えad35ベクター及び関連遺伝子治療改善 |
CN112898412A (zh) * | 2019-12-03 | 2021-06-04 | 复旦大学 | 一种高稳定性类Fab抗体及其制备方法和应用 |
IL293310A (en) | 2019-12-18 | 2022-07-01 | Hoffmann La Roche | Bispecific anti-ccl2 antibodies |
CN114981297A (zh) | 2019-12-23 | 2022-08-30 | 戴纳立制药公司 | 颗粒蛋白前体变体 |
BR112022011723A2 (pt) | 2019-12-27 | 2022-09-06 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-ctla-4 e uso do mesmo |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multi-target antibodies for use in the treatment of diseases |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
SG11202105302PA (en) | 2020-03-31 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
EP4146695A1 (de) | 2020-05-04 | 2023-03-15 | Immunorizon Ltd. | Vorläufertrispezifische antikörperkonstrukte und verfahren zur verwendung davon |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
JP2023538098A (ja) | 2020-08-21 | 2023-09-06 | ジェンザイム・コーポレーション | Fgfr3抗体および使用の方法 |
US20230416371A1 (en) | 2020-08-28 | 2023-12-28 | Chugai Seiyaku Kabushiki Kaisha | Heterodimer fc polypeptide |
IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
EP4305065A1 (de) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Cd3 und gpc3 bindende heterodimere antikörper |
JP2024515303A (ja) * | 2021-04-19 | 2024-04-08 | ヤンセン バイオテツク,インコーポレーテツド | 操作された抗体定常領域変異体を有する分子 |
IL308163A (en) | 2021-05-03 | 2024-01-01 | Merck Patent Gmbh | FC antigen-binding conjugate drug fragments targeting HER2 |
WO2022248380A1 (en) | 2021-05-25 | 2022-12-01 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
CA3221735A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
WO2022270611A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体 |
WO2022270612A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体の使用 |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
WO2024042105A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic |
WO2024042104A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG70553A1 (en) | 1984-03-01 | 2000-02-22 | Univ Leland Stanford Junior | T-cell receptor-specific for antigen polypeptides and related polynucleotides |
DE3590766C2 (de) * | 1985-03-30 | 1991-01-10 | Marc Genf/Geneve Ch Ballivet | |
US6492107B1 (en) * | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5892019A (en) * | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JP3283041B2 (ja) | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5395750A (en) * | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
ATE165113T1 (de) | 1992-05-08 | 1998-05-15 | Creative Biomolecules Inc | Mehrwertige chimäre proteine anologe und verfahren zu deren anwendungen |
WO1994007921A1 (en) * | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
US6194166B1 (en) * | 1993-05-24 | 2001-02-27 | Takara Shuzo Co., Ltd. | Gene regulating aureobasidin sensitivity |
US5536814A (en) | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
WO1995031483A1 (en) * | 1994-05-13 | 1995-11-23 | Eclagen Limited | Improvements in or relating to peptide delivery |
GB9501079D0 (en) * | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
AUPO591797A0 (en) * | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6352842B1 (en) * | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
US6361974B1 (en) * | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US6358709B1 (en) * | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
AU6685698A (en) | 1997-03-07 | 1998-09-22 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6477506B1 (en) * | 1998-02-23 | 2002-11-05 | Sony Corporation | Terminal apparatus, information service center, transmitting system, and transmitting method |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6376246B1 (en) * | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
EP1108783A3 (de) | 1999-01-19 | 2001-09-05 | Maxygen, Inc. | Oligonukletiden-gesteuerte Nukleinsäurerekombination |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
AU3391900A (en) * | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
CA2373721C (en) | 1999-07-02 | 2013-10-15 | Genentech, Inc. | Compounds that bind her2 |
DE60040556D1 (de) | 1999-12-06 | 2008-11-27 | Univ Illinois | Hochaffine t-zellrezeptorproteine und verfahren |
EP1118661A1 (de) | 2000-01-13 | 2001-07-25 | Het Nederlands Kanker Instituut | T-Zellrezeptor-Bibliotheken |
JP2003274960A (ja) | 2000-02-03 | 2003-09-30 | Japan Science & Technology Corp | 可溶性t細胞受容体タンパク質およびその作成方法 |
WO2001062908A2 (en) | 2000-02-22 | 2001-08-30 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
AU2001243670A1 (en) | 2000-03-20 | 2001-10-03 | Maxygen, Inc. | Method for generating recombinant dna molecules in complex mixtures |
CA2407956A1 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2001088159A2 (en) | 2000-05-16 | 2001-11-22 | Euro-Celtique S.A. | Cd28 synthebody for the modulation of immune responses |
CA2409991A1 (en) * | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
WO2002006469A2 (en) | 2000-07-18 | 2002-01-24 | Enchira Biotechnology Corporation | Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids |
JP2002058479A (ja) | 2000-08-14 | 2002-02-26 | Canon Inc | 構造認識アミノ酸配列の取得方法 |
AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
EP1341812A2 (de) * | 2000-11-08 | 2003-09-10 | Incyte Genomics, Inc. | Sekretierte proteine |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
EP1355919B1 (de) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
ES2389251T3 (es) | 2000-12-19 | 2012-10-24 | Altor Bioscience Corporation | Animales transgénicos que comprenden un sistema inmunitario humanizado |
IL141539A0 (en) | 2001-02-20 | 2002-03-10 | Yeda Res & Dev | Dna molecules and cells transfected therewith |
US20030157561A1 (en) * | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
CA2444854A1 (en) * | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
EP1281757A1 (de) | 2001-07-31 | 2003-02-05 | Direvo Biotech AG | Methode zur Herstellung von Nukleinsäuren mit stochastisch kombinierten Abschnitten von Ausgangsnukleinsäuren |
PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
EP2093286B1 (de) | 2001-10-01 | 2013-02-27 | Dyax Corporation | Mehrkettige eukaryotische Display-Vektoren und deren Verwendungen |
EP1446418B1 (de) | 2001-10-22 | 2012-05-23 | The Scripps Research Institute | Auf integrin zielende verbindungen |
US20040043424A1 (en) * | 2001-11-15 | 2004-03-04 | Baughn Mariah R | Immunoglobulin superfamily proteins |
EP2075256A2 (de) | 2002-01-14 | 2009-07-01 | William Herman | Gezielte Liganden |
US20040063924A1 (en) * | 2002-01-28 | 2004-04-01 | Y Tom Tang | Secreted proteins |
US20030157091A1 (en) * | 2002-02-14 | 2003-08-21 | Dyax Corporation | Multi-functional proteins |
AU2003219810A1 (en) * | 2002-02-19 | 2003-09-09 | Syntherica Corporation | Compositions and methods for surrogate antibody modulation of an immune response and transport |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
PT1916001E (pt) | 2002-03-04 | 2011-07-18 | Imclone Llc | Anticorpos humanos específicos para kdr e suas utilizações |
US20040097711A1 (en) * | 2002-03-12 | 2004-05-20 | Henry Yue | Immunoglobulin superfamily proteins |
EP1394251A1 (de) | 2002-08-23 | 2004-03-03 | Direvo Biotech AG | Verfahren zur selektiven Zufallsmutagenese von Polynukleotiden |
WO2004033685A1 (en) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
DK1558643T3 (da) | 2002-11-09 | 2009-09-07 | Immunocore Ltd | Cellereceptorpr sentation |
JP2006523437A (ja) | 2002-12-03 | 2006-10-19 | アヴィデックス リミテッド | レセプター複合体 |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
WO2005021595A1 (en) | 2003-08-28 | 2005-03-10 | Euro-Celtique S.A. | Methods of antibody engineering using antibody display rules |
ES2364147T3 (es) | 2004-01-16 | 2011-08-25 | Regeneron Pharmaceuticals, Inc. | Polipéptidos de fusión capaces de activar receptores. |
WO2005092925A2 (en) * | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
CA2567349C (en) | 2004-05-19 | 2012-11-27 | Avidex Ltd | Method of improving t cell receptors |
EP1765860B1 (de) | 2004-05-19 | 2008-12-10 | MediGene Ltd. | Hochaffiner ny-eso-t-zellen-rezeptor |
GB0411773D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex |
KR20150140417A (ko) | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Her2 항체 조성물 |
ES2629397T3 (es) | 2004-09-24 | 2017-08-09 | Amgen Inc. | Moléculas de Fc modificadas |
CA2582963A1 (en) | 2004-10-01 | 2006-04-13 | Avidex Ltd | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
EP1810035A4 (de) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | Erzeugung von fc-antikörperregionen für effektorfunktion |
US20080274133A1 (en) | 2004-11-18 | 2008-11-06 | Avidex Ltd. | Soluble Bifunctional Proteins |
GB0425732D0 (en) | 2004-11-23 | 2004-12-22 | Avidex Ltd | Gamma-delta t cell receptors |
PT2028193E (pt) | 2005-01-05 | 2012-06-15 | Star Biotech Forschung Entw Gmbh | Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade |
GB0503546D0 (en) | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US20080227958A1 (en) | 2006-04-14 | 2008-09-18 | Trubion Pharmaceuticals Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
AT503889B1 (de) * | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
US7514271B2 (en) | 2007-03-30 | 2009-04-07 | International Business Machines Corporation | Method of forming high density planar magnetic domain wall memory |
EP1975178A1 (de) | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transzytotischer modularer Antikörper |
US8921279B2 (en) | 2007-06-26 | 2014-12-30 | F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H | Display of binding agents |
JP5889533B2 (ja) | 2008-01-31 | 2016-03-22 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改変された抗体定常ドメイン分子 |
EP2113255A1 (de) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Zytotoxisches Immunglobulin |
EP2451838A1 (de) | 2009-07-09 | 2012-05-16 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Stabilisierte konstante domänen von immunglobulin |
US20120010388A1 (en) | 2010-04-16 | 2012-01-12 | Gottfried Himmler | LeY SPECIFIC BIOTHERAPEUTIC |
EP2407487A1 (de) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispezifische modulare Antikörper |
US20140087957A1 (en) | 2012-09-25 | 2014-03-27 | Marko Vuskovic | Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes |
GB201317622D0 (en) | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
-
2006
- 2006-01-05 PT PT08168439T patent/PT2028193E/pt unknown
- 2006-01-05 AT AT08168439T patent/ATE548386T1/de active
- 2006-01-05 PL PL06011173T patent/PL1772465T3/pl unknown
- 2006-01-05 CN CN201310486561.2A patent/CN103555733A/zh active Pending
- 2006-01-05 KR KR1020137018696A patent/KR20130105885A/ko not_active Application Discontinuation
- 2006-01-05 PL PL06121439T patent/PL1752471T3/pl unknown
- 2006-01-05 SI SI200630199T patent/SI1752471T1/sl unknown
- 2006-01-05 ES ES08168439T patent/ES2384039T3/es active Active
- 2006-01-05 DK DK08168439.1T patent/DK2028193T3/da active
- 2006-01-05 CN CN200680001831.4A patent/CN101098891B/zh active Active
- 2006-01-05 WO PCT/EP2006/050059 patent/WO2006072620A1/en active Application Filing
- 2006-01-05 EP EP06121439A patent/EP1752471B9/de active Active
- 2006-01-05 NZ NZ555893A patent/NZ555893A/en unknown
- 2006-01-05 MX MX2007008118A patent/MX2007008118A/es active IP Right Grant
- 2006-01-05 AT AT06121439T patent/ATE414718T1/de active
- 2006-01-05 EP EP06011173A patent/EP1772465B1/de active Active
- 2006-01-05 SI SI200630280T patent/SI1772465T1/sl unknown
- 2006-01-05 EP EP06703578A patent/EP1699826B1/de active Active
- 2006-01-05 KR KR20077014725A patent/KR101404512B1/ko active IP Right Grant
- 2006-01-05 ES ES06121439T patent/ES2320374T3/es active Active
- 2006-01-05 DK DK06703578T patent/DK1699826T3/da active
- 2006-01-05 SI SI200630309T patent/SI1699826T1/sl unknown
- 2006-01-05 BR BRPI0606399A patent/BRPI0606399A8/pt not_active Application Discontinuation
- 2006-01-05 AT AT06703578T patent/ATE425186T1/de active
- 2006-01-05 RS RSP-2009/0212A patent/RS50785B/sr unknown
- 2006-01-05 CA CA2594356A patent/CA2594356C/en active Active
- 2006-01-05 PL PL06703578T patent/PL1699826T3/pl unknown
- 2006-01-05 AT AT06011173T patent/ATE423140T1/de active
- 2006-01-05 RS RSP-2009/0076A patent/RS50752B/sr unknown
- 2006-01-05 US US11/722,517 patent/US20090298195A1/en not_active Abandoned
- 2006-01-05 DE DE602006005526T patent/DE602006005526D1/de active Active
- 2006-01-05 ES ES06011173T patent/ES2321861T3/es active Active
- 2006-01-05 DK DK06121439T patent/DK1752471T3/da active
- 2006-01-05 PT PT06703578T patent/PT1699826E/pt unknown
- 2006-01-05 RS RSP-2009/0267A patent/RS50830B/sr unknown
- 2006-01-05 DE DE602006003695T patent/DE602006003695D1/de active Active
- 2006-01-05 EP EP08168439A patent/EP2028193B1/de active Active
- 2006-01-05 ES ES06703578T patent/ES2323651T3/es active Active
- 2006-01-05 PT PT06121439T patent/PT1752471E/pt unknown
- 2006-01-05 JP JP2007549891A patent/JP4937138B2/ja active Active
- 2006-01-05 EA EA200701443A patent/EA018897B1/ru not_active IP Right Cessation
- 2006-01-05 DE DE602006005200T patent/DE602006005200D1/de active Active
- 2006-01-05 PT PT06011173T patent/PT1772465E/pt unknown
- 2006-01-05 DK DK06011173T patent/DK1772465T3/da active
- 2006-01-05 AU AU2006204459A patent/AU2006204459B2/en active Active
-
2007
- 2007-06-21 IL IL184103A patent/IL184103A/en active IP Right Grant
-
2009
- 2009-02-12 HR HR20090087T patent/HRP20090087T3/xx unknown
- 2009-02-18 CY CY20091100172T patent/CY1108767T1/el unknown
- 2009-04-20 HR HR20090228T patent/HRP20090228T1/xx unknown
- 2009-05-18 CY CY20091100528T patent/CY1110895T1/el unknown
- 2009-06-02 HR HR20090326T patent/HRP20090326T1/xx unknown
- 2009-06-11 CY CY20091100617T patent/CY1109143T1/el unknown
-
2011
- 2011-05-31 US US13/149,871 patent/US9856311B2/en active Active
- 2011-06-01 US US13/151,195 patent/US9045528B2/en active Active
- 2011-06-01 US US13/151,207 patent/US20110251375A1/en not_active Abandoned
- 2011-12-19 JP JP2011277069A patent/JP5483294B2/ja active Active
-
2013
- 2013-12-17 JP JP2013260218A patent/JP5717833B2/ja active Active
-
2017
- 2017-03-31 US US15/476,029 patent/US10385118B2/en active Active
-
2019
- 2019-04-16 US US16/386,067 patent/US11084868B2/en active Active
- 2019-11-22 US US16/692,220 patent/US11499249B2/en active Active
-
2022
- 2022-10-11 US US17/963,509 patent/US20230340696A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE548386T1 (de) | Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften | |
CY1120723T1 (el) | Ανταγωνιστικα αντισωματα il-17 | |
ATE476994T1 (de) | Antikörper gegen gpnmb und ihre verwendungen | |
ZA200702879B (en) | Single domain antibodies against TNFR1 and methods of use therefor | |
NO2017032I1 (no) | bezlotoksumab | |
RS53168B (en) | Antibodies and Immunoconjugates and Their Use | |
CY1113400T1 (el) | Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση | |
CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
RS53760B1 (en) | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES | |
CY1119890T1 (el) | Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1 | |
NZ585622A (en) | Hepatitis c virus antibodies | |
EA200700876A1 (ru) | Агенты, специфически связывающие ангиопоэтин-2 | |
DK1771732T3 (da) | Taxol-immunassay | |
DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
ATE482980T1 (de) | Antikörper variable region eines monoklonalen antikörpers gegen den humanen tumor nekrose faktor-alpha und dafür kodierendes gen | |
EA202190599A1 (ru) | Анти-tigit антитела | |
EA201992039A1 (ru) | Антитела к tigit |